Addex Therapeutics Ltd
ISIN: CH0029850754 | Ticker: ADXN | LEI: 89450068Y9KVP2MQGH86
Country: Switzerland
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.
Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.
Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is in a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID).
2002
Served areaWorldwide
Headcount28
HeadquartersChemin des Aulx 12, 1228 Plan-les-Ouates – Switzerland
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 27.11.23 | None | Executive member | Buy | CHF 301,345.00 |
| 27.11.23 | None | Executive member | Buy | CHF 53,760.00 |
| 27.11.23 | None | Executive member | Buy | CHF 45,450.00 |
| 27.11.23 | None | Non-Executive member | Buy | CHF 44,856.00 |
| 27.11.23 | None | Non-Executive member | Buy | CHF 24,423.00 |
| 27.11.23 | None | Executive member | Buy | CHF 5,487.00 |
| 27.11.23 | None | Non-Executive member | Buy | CHF 3,927.00 |
| 27.11.23 | None | Executive member | Buy | CHF 2,150.00 |
CH0029850754
LEI89450068Y9KVP2MQGH86
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.